| Literature DB >> 33071352 |
Nayim Sepay1, Aishwarya Sekar2, Umesh C Halder1, Abdullah Alarifi3, Mohd Afzal3.
Abstract
Traditional medicines contain natural products (NPs) as main ingredient which always give new direction and paths to develop new advanced medicines. In the COVID-19 pandemic, NPs can be used or can help to find new compound against it. The SARS coronavirus-2 main protease (SARS CoV-2 Mpro) enzyme, arbitrate viral replication and transcription, is target here. The study show that, from the electronic features and binding affinity of all the NPs with the enzyme, the compounds with higher hydrophobicity and lower flexibility can be more favorable inhibitor. More than fifty NPs were screened for the target and one terpenoid (T3) from marine sponge Cacospongia mycofijiensis shows excellent SARS CoV-2 Mpro inhibitory activity in comparison with known peptide based inhibitors. The molecular dynamics simulation studies of the terpenoids with the protein indicates that the complex is stable and hydrogen bonds are involved during the complexation. Considering binding affinity, bioavailability, pharmacokinetics and toxicity of the compounds, it is proposed that the NP T3 can act as a potential drug candidate against COVID-19 virus.Entities:
Keywords: ADME; ATAD5, ATPase family AAA domain-containing protein 5; Ahr, aryl hydrocarbon receptor; Ar, androgen receptor; Ar-lbd, androgen receptor ligand binding domain; Cyto, cytotoxicity; Dili, hepatotoxicity carcino carcinogenicity; Docking; Er, estrogen receptor alpha; Er-lbd, estrogen receptor ligand binding domain; HSE, Heat shock factor response element; MMP, Mitochondrial Membrane Potential; Molecular dynamics; Mutagen, mutagenicity; Natural products; PPAR-Gamma, Peroxisome Proliferator Activated Receptor Gamma; Sars cov-2 mpro; Toxicity; nrf2/ARE, Nuclear factor (erythroid-derived 2)-like 2/antioxidant responsive element; sars, severe acute respiratory syndrome
Year: 2020 PMID: 33071352 PMCID: PMC7547581 DOI: 10.1016/j.molstruc.2020.129433
Source DB: PubMed Journal: J Mol Struct ISSN: 0022-2860 Impact factor: 3.196
Fig. 1The required structural features for a good covalent as well as non-covalent SARC—CoV-2 Mpro inhibitor.
Docking score of different types of NPs and the SARC—CoV-2 Mpro co-crystallized peptides with the enzyme.
Fig. 2The stereochemical features of inhibitor NPs show high binding affinity with SARC—CoV-2 Mpro.
Fig. 3Docking pose and binding interactions of NPs (a) T3 and (b) T14 inside the SARC CoV-2 Mpro binding site.
Fig. 4Predicted lipophilicity (log P values) and water solubility (log S values) of NPs by different calculation models.
Fig. 5(a) Root mean square deviation (RMSD) of backbone atoms of SARS-CoV2 Mpro (Mpro) protein (red) and with T3 ligand (blue), (b) Root Mean Square fluctuations of Mpro in complex with T3, (c) Number of hydrogen bonds between Mpro and the natural compound T3.